Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline.

Combined CYP2B6/CYP2C9/CYP2C19/CYP2D6/CYP3A4 activity score corrected for phenoconversion — prediction of adverse effects and clinical improvement on sertraline

In 347 youth (ages 6–24) receiving sertraline for mental health conditions, combined CYP2B6/CYP2C9/CYP2C19/CYP2D6/CYP3A4 activity scores, corrected for phenoconversion, were associated with both symptom improvement and side effects. Higher combined CYP450 activity was associated with reduced odds of symptom improvement (OR 0.060) and side effects (OR 0.097). These findings suggest that a multi-gene CYP450 activity score may serve as a pharmacogenetic marker to personalize sertraline use in pediatric and young adult populations.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Phenoconversion correction is a methodologically important and often neglected aspect of pharmacogenetic studies: concomitant medications can profoundly alter functional CYP phenotypes. This pediatric sertraline study — a widely used antidepressant in child and adolescent psychiatry — provides valuable data supporting preemptive multi-gene CYP genotyping in this age group, where treatment response variability is particularly impactful.

Clinical impact : 2/3 · Evidence strength : 2/3 · Novelty : 2/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 8/10